Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
let's finish off CDEL here and we've got a shot at .50 today it seems
Good luck all I'm out today... Money needs to go somewhere else... I can see this one running hard one day though.. With that said knowing my luck (family creed meaning luckless fellow) LXRP is going to spike up for a bit because that is the luck I have.. So Enjoy... :)
manipulation at its best. hope this POS gets busted.
Sure why not, sounds totally good for me.
NITE is playing with himself, every time ask hit bid grows, every time bid hit ask grows. WTF.
paddle that ask, I want to see .50 today!
haha yup, bid probably not high enough for them yet
Usual whackers must still be snoozing out on West coast
nice slaps on the ask, we get past .48 looks like this can get some legs
BMAK is out and the chunk from CDEL is getting eaten up!!
Bring on .50 $LXRP
news clip from the conference that Lexaria presented at earlier today...
https://globalnews.ca/news/3771322/investing-in-marijuana-business-ahead-of-legalization-full-of-risks-and-potential-rewards/
No Bunka/Lexaria in the clip, but puts you there for a few seconds.
this most recent rise has been nice and steady - should help hold gains
totally agree on that, it all starts with believing in what you are selling.
No, but I have watched Chris grow with each presentation. I have confidence that he will land the big one. He believes in the value of LXRP technology.
were you able to attend today?
Chris has improved drastically from his earlier presentations. More focused and confident.
still not in the power zone yet
turd burglar BMAK trying to get his bid fed
We are just analyzing based upon available information; In reality the only one who truly knows is the short. I have enjoyed the conversation though :)
I will be out of the area and probably offline until late Friday.
Hang in there Lexarians there are good times ahead,
Knife
Hope I'm wrong and and that it's just some shorter asses waiting to be burned.
I looked at the trading back from March 1st into April. There were 2 pops to 52-ish US with enough volume which is about a 20% spread. If your plan is to not lose a penny on the deal, a few percentage point profit works. The rest of us pray for 1000%. :D
It is all the same, Form 9 shows Payment date of April 3rd which is what is on the 8K. Different form same overall information.
As stated previously virtually all the shorting was done in March. I am not saying they did not short into the PP. I am saying that if they are using .42 warrant shares to cover then based upon price fluctuations in March they will be losing $$ on much of the cover.
We will find out soon enough (COB, 10 Oct) if there is a large cover or not. If resistance at .48 breaks and the price spikes as I expect prior to 10 Oct then it may be difficult to tell if it is a PP cover or was covering from the breakout.
Find out soon enough,
Knife
nice hit!! Chris must be making waves at that conference!
hopefully some lasting impressions are made...would be nice to get over .50 this week
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it will be attending and delivering a presentation at the upcoming Canadian Securities Exchange sponsored "Cannabis in the Capital Markets" event on September 27, in Kelowna, British Columbia. Also presenting at the event will be Dr. Philip Ainsle, Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, who will be Principal Investigator of the previously announce clinical study to be conducted by UBC and Lexaria.
Chris must be making some impressions today.
ask slapping again, let's break down this .47 barrier before close!
form 9 is dated March 30, 2017.
http://thecse.com/sites/default/files/2017_03_30_Form_9_-_Amended_Notice_of_Completed_Private_Placement.pdf
I'll go with Monday to be safe.
There was already 477k shorted as per FINRA on March 15th.
Why assume they wouldn't short into the PP?
bid continuing to improve and so far no whacks
I will assume you mean the April 3rd private placement (8k filed April 6th). If it is from there then we will still find out with the next FINRA update if they cover or not.
The shorting was all done in March; Per FINRA the short position went from 24,787 Feb 28th to 842,743 by March 31st. Considering much of the month of March the price was well below the .42 private offering price then covering the short using these shares would be a loss would it not?
In any case LXRP will be fun to ride into the future,
All the best,
Knife
you're forgetting the private placement on March 30, 2017. Those shares are released on Monday.
The run-up happened around January/February. Someone that participated in the PP, shorted 800K-ish shares (which they do not have on hand to pay back until Monday - so that FINRA number just waits, regardless of the current price). Going forward, they will only hold the 60 cent US warrants as of Monday. They de-risked to zero on their shares and already made their profit. Warrants are gravy.
Yep, the theory has been around for a while that the short is one of the Warrant holders and will cover the short when they convert the Warrants. However, the Short position (per Finra) has been over 800k for six months now even with the many warrant conversions during that time frame. Every time there is a big conversion we think the short # will tank and it has not. Even this recent 625K share conversion was set to expire on Sept 15 so it had to be converted prior to then and the most recent short numbers were due to FINRA by the 15th for posting yesterday. One would think that if this batch was the short they would have covered immediately since the price was pushing upward yet the short # remains virtually unchanged. There may have been a timing issue with the update being that the days lined up so closely but we will confirm the cover or not with the next FINRA release on 10 Oct (End of Day).
In the meantime I like looking back at when the short position originated, the month of March. If the big short has just been sitting on the position (as it seems) then most of the shorted shares would be out of the money at the current share price. With the chart in a nice Ascending Triangle (very bullish) and resistance at .48 being tested I would expect to see some big buy covers coming soon.
This is just my thinking on the subject, I have been wrong before.
All the best,
Knife
haha yup, usually right at open when the sellers are still sleeping
LXRP always gets crazy ask pressure when the dipshit sell squad isn't paying attention
I do like seeing the accumulation of bidders at .43+, just need to keep working them up to meet the ask
Mucho ask donkeys tripping over each other like a bunch of noobs
Isn't the theory that its shorted against the shares that will be released very "shortly" and that will be used to cover? Anson partners or whoever those nutsacks are
They may be getting a bit nervous eh? lol
Good times ahead,
Knife
agreed, I believe that's why BMAK is on the bid
Canadian side up to .55, we seem to follow them
Nice to see there are still 865K shares short per FINRA (as of 9-15).
http://otce.finra.org/ESI
Even a slow short cover will push up the share price nicely.
All the best,
Knife
haha now that would be amazing....2.6B mkt cap
but I'd be extremely wealthy - so I'm in
I'm thibking, Buy out price $38.60
let's wall up at .47 lol that will help.
there are some real stupid traders out there
Very few tickers in the OTC that can be held long term but LXRP is one of them GLA
story of our lives here lol
Bid support, quick - whack it lol
Next key resistance IMO is .48. Break and hold above it and I will be content for the week :) The big run will come on news soon enough. It is easy to be long term with LXRP when you have done your DD.
Buy-Hold-Retire before your old,
Knife
Nice open shame it did not last long still promising sign. Lucky charm? I'd like to think so. The DD on LXRP speaks for it's self CEO , patents licensing etc just need patience. Bought 500000 AMFE a while ago now.17 going to dollars, nearly sold them a couple a times because of lack of patience. Buying more here on dips and have been for a while will pay off in the end
Followers
|
220
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
34624
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |